Asthma

Results from the TRIMARAN and TRIGGER trials show significant benefits for 2 different doses of the ICS/LABA/LAMA combination.

A new study from ERS showed the technological material common among training athletes could help physicians monitor patients with COPD.

A new study from the ERS International Congress shows a trio of air pollutants are associated with significant increases in all-cause infant mortality in the UK.

A comparative assessment of step-up therapy strategies for black patients with inadequately controlled asthma showed varying responses.

After receiving FDA approval for add-on adult severe chronic rhinosinusitis with nasal polyps treatment this June, the biologic has reported significant improvement in 24- and 52-week outcomes.

On this episode of the DocTalk Podcast, Lakiea Wright, MD, of Brigham and Women's Hospital and Thermo Fisher Scientific, discusses the impact of changing seasons and climate on allergies and asthma.

A new study shows that approximately one-quarter of adults aged 18-34 years old with a medical condition have used marijuna in the past month.

The biologic becomes the first in its drug class to be indicated for patients aged 6-11 years old with the difficult-to-treat condition.

Obstructive sleep apnea has been consistently underdiagnosed in US populations. Are screening methods enough?

Addressing the drivers of poor sleep conditions is among the many ways a physician can treat patients without prescription.

How a pattern of poor sleep could begin a cycle of worsened respiratory and cardiovascular health.

Dr. Rizzo provides a look into the current methods of COPD screening, and how patient treatment potential is changed.

Particle-depleted diesel exhaust may impair a person's lung function worse than just standard diesel exhaust—while also exposing them to more NO2.

How do at-risk exacerbation patients present, and what developing therapies could benefit them?

Air pollution is driving pediatric risk for lung disease. Are there therapies at hand to address it?

Investigative triple therapy PT010 from AstraZeneca has reached primary outcome results versus a pair of standard dual inhaled therapies.

A study comparing the LABA agent to maintenance therapy showed results supporting recent GINA recommendations for mild asthma management.

What is the large-scale study looking to bring to clinical respiratory health understanding?

In what ways do the respiratory conditions differentiate in progression and care options?

A 600-city analysis of particulate matter found daily exposure is linked to worsened mortality rates, particularly in areas with higher mean temperatures.

In a population-based cohort study, investigators discover how allergy immunotherapy helps allergic rhinitis from progressing to asthma.

The first longitudinal study to assess air pollution and emphysema progression provides novel long-term findings.

A new study found significantly greater COPD development risk among middle-aged women who eat processed meat—and doubly worse risk for those who also smoke and have unhealthy diets.

Analysis from the CARDIA Lung study found patients with worsened FEV1 are at greater risk for emphysema, regardless of their smoker status.

A secondary analysis of a 10,000-patient study has linked lower levels of serum albumin to apnea risk in hospitalized infants.